$29.13
+6.2%Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
TECX • NASDAQ
| Tectonic Therapeutic, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
253.8M | 141.2M | 28.8M | 36M | 28.1M | 259.7M | 187M | 126.3M | 6M | 5.4M | |
253.8M | 141.2M | 28.8M | 36M | 28.1M | 259.7M | 187M | 126.3M | 6M | 5.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.6M | 2.1M | 1.5M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.6M | 2.1M | 1.5M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.7M | 5.9M | 1.4M | 285K | 15K | |
3.6M | 5.6M | 2.1M | 1.1M | 557K | 271K | 620K | 795K | 60K | 4K | |
257.4M | 146.9M | 30.9M | 37M | 28.6M | 267.2M | 195.7M | 130M | 6.3M | 5.4M | |
NON-CURRENT ASSETS | ||||||||||
2.6M | 5.3M | 7.2M | 9.6M | 3.7M | 3.1M | 3.7M | 2.6M | 349K | 0.0 | |
0.0 | 587K | 0.0 | 0.0 | 0.0 | 492K | 492K | 492K | 24K | 24K | |
1.1M | 156K | 1.3M | 613K | 599K | 436K | 625K | 333K | 341K | 0.0 | |
3.7M | 6M | 8.5M | 10.2M | 4.3M | 4M | 4.8M | 3.5M | 714K | 24K | |
261M | 152.9M | 39.4M | 47.2M | 32.9M | 271.2M | 200.5M | 133.5M | 7M | 5.4M | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
1.1M | 976K | 409K | 574K | 1.8M | 2.7M | 3.9M | 2.8M | 527K | 340K | |
1.1M | 976K | 409K | 574K | 1.8M | 2.7M | 3.9M | 2.8M | 527K | 340K | |
0.0 | 4.3M | 5.3M | 3.2M | 198K | 6.4M | 3M | 2.6M | 794K | 374K | |
1.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 2.8M | 1.8M | 1.4M | 355K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
7.3M | 3.6M | 33.4M | 2.7M | 1.8M | 7.5M | 7M | 5.2M | 1.3M | 177K | |
9.7M | 11.6M | 40.9M | 7.8M | 4.1M | 16.6M | 14M | 10.6M | 2.6M | 891K | |
NON-CURRENT LIABILITIES | ||||||||||
43K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 80.6M | 80.7M | 43M | 276K | 484K | 689K | 1M | 88K | |
43K | 519K | 83.1M | 85M | 43.7M | 276K | 484K | 689K | 1M | 88K | |
0.0 | 3.3M | 4.3M | 5.8M | 1.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
9.7M | 12.1M | 124M | 92.9M | 47.8M | 16.9M | 14.5M | 11.3M | 3.7M | 979K | |
SHAREHOLDERS' EQUITY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 26.5M | 9M | |
2K | 2K | 0.0 | 0.0 | 0.0 | 4K | 3K | 2K | 1K | 1K | |
0.0 | 289.4M | 6M | 2.1M | 641K | 518.8M | 330.7M | 193.9M | 0.0 | 0.0 | |
-222.7M | -148.6M | -90.6M | -47.8M | -15.6M | -264.4M | -144.7M | -71.7M | -23.5M | -4.8M | |
-96K | 9K | -11K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1K | -1K | |
474.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 340K | 248K | |
251.3M | 140.8M | -84.6M | -45.7M | -15M | 254.3M | 186M | 122.2M | 3.4M | 4.4M | |
251.3M | 140.8M | -84.6M | -45.7M | -15M | 254.3M | 186M | 122.2M | 3.4M | 4.4M | |
SUMMARY | ||||||||||
261M | 152.9M | 39.4M | 47.2M | 32.9M | 271.2M | 200.5M | 133.5M | 7M | 5.4M | |
0.0 | 587K | 0.0 | 0.0 | 0.0 | 492K | 492K | 492K | 24K | 24K | |
1.3M | 3.3M | 4.3M | 5.8M | 1.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-252.5M | -137.9M | -24.4M | -30.2M | -27M | -259.7M | -187M | -126.3M | -6M | -5.4M | |
18,712,128 | 18,712,128 | 18,712,128 | 18,712,128 | 18,712,128 | 18,712,128 | 18,712,128 | 18,712,128 | 18,712,128 | 18,712,128 |
TECX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 23, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 29, 2025 | 2025 |
Continue your TECX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.